XORTX Therapeutics Inc.
XRTX
Last
$1.41
Day
-23.8%
1y
-59.2%
5y
-99.0%
52w
-73.8%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1333d
EMA 21
1.83
EMA 50
1.96
EMA 200
2.46
20d high
-30.2%
5y high
-99.3%
5y range
0th
Positions held
Your positionsXRTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-10
Hold
avoid
Signal
Sell
Target
$2.03
Stop
$1.70
Stop distance
20.6%
Target vs last
+44.0%
Fundamentals
| Market cap | $3.36M | Enterprise value | $2.37M | Trailing P/E | — | Forward P/E | 2.31 |
| PEG | — | Price / book | 1.24 | Beta | 0.58 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -99.2% | ROA | -29.9% | Debt / equity | — |
| Current ratio | 3.59 | Free cash flow | -$2.58M | Analyst recommendation | none | Mean target | — |
| 52w high | $7.05 | 52w low | $1.59 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$1.7M | -$0.8M | -$0.6M | -$0.6M | -$0.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$1.7M | -$0.8M | -$0.7M | -$0.7M | -$0.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$2.7M | -$3.3M | -$2.2M | -$7.7M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$3.3M | -$4.1M | -$6.0M | -$10.3M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
2026-09-10 · XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
2026-09-08 · XORTX Re-Engages Investor Relations Program
2026-08-28 · XORTX Announces Termination and Postponement of Investor Relations Program
2026-07-31 · XORTX Announces Director Resignation
2026-07-29 · XORTX Appoints New Director
Price (daily)
Full chart · RSI · MACD · patternsXRTX · daily-0.5% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin